Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TAC-100 by Triumvira Immunologics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
TAC-100 is under clinical development by Triumvira Immunologics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...
Data Insights
TAC-100 by Triumvira Immunologics for Esophageal Cancer: Likelihood of Approval
TAC-100 is under clinical development by Triumvira Immunologics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...